Gene Editing Therapeutics Market

Market Research Report | 2024-08-30 | 111 pages | BCC Research

AVAILABLE LICENSES:

- Single User License $5500.00
- 2-5 Users License $6600.00
- Site License $7920.00
- Enterprise License $9504.00

Report description:

Description

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

- 15 data tables and 42 additional tables
- An analysis of the current and future global markets for gene editing therapeutics
- Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
- Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
- Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
- Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
- Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Executive Summary

Summary:

Gene editing is a technique that precisely alters the genome sequence to introduce insertions, deletions or base substitutions. This technology holds promise for controlling diseases at the genetic level, particularly those genetic disorders caused by mutations in a single gene, as many diseases are associated with changes in gene expression in vivo. The evolution of gene editing technology can be categorized into three main generations: the first generation involves zinc-finger nucleases (ZFNs), the second generation utilizes transcription activator-like effector nucleases (TALENs), and the third and most widely used generation is the CRISPR/Cas9 system. Unlike ZFNs and TALENs, which target DNA strands using proteins, CRISPR technology guides Cas proteins to specific genome locations by altering the base sequence of a guide RNA segment, thereby enhancing gene editing efficiency and broadening the technology's applicability.

Gene editing therapeutics gained prominence over the last decade. The first therapeutic, Casgevy (exagamglogene autotemcel [exa-cel]), developed jointly by CRISPR Therapeutics and Vertex Pharmaceuticals, was approved in the U.K. in November 2023 and in the U.S. in December 2023. The approval of the first CRISPR/Cas9-based gene editing therapy is a game changer in this field. Casgevy is approved for genetic diseases, including sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT).

The gene editing therapeutics market consists of numerous small biotech firms that have been conducting research in this field. Approval of the first therapy has provided momentum to many of these companies. Numerous clinical trials are being conducted by various clinical stage biotech firms, but the majority of these trials are in the early stage of development. Approval of these therapies during the forecast period is therefore unlikely. The only product from Intellia Therapeutics, NTLA-2001, used for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), is in Phase III stage of development. The trial MAGNITUDE (NCT06128629) has its primary completion date listed as December
2027 and its estimated completion date as April 2028. If the ongoing pivotal trial has a positive outcome, the product will likely enter the market in late 2029 or sometime in 2030.

Table of Contents:

Company Profiles
ALLOGENE THERAPEUTICS
BEAM THERAPEUTICS
CARIBOU BIOSCIENCES INC.
CRISPR THERAPEUTICS
EDITAS MEDICINE
INTELLIA THERAPEUTICS INC.
PRECISION BIOSCIENCES
SANGAMO THERAPEUTICS
VERTEX PHARMACEUTICALS INC.
VERVE THERAPEUTICS INC.
VOR BIO

SCOTTS INTERNATIONAL

Gene Editing Therapeutics Market

Market Research Report | 2024-08-30 | 111 pages | BCC Research

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$5500.00
	2-5 Users License	$6600.00
	Site License	$7920.00
	Enterprise License	$9504.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-03-04
		Signature